Corporate
-
Alliances & Joint Ventures
Orchid ties up with Mayne Pharma
Our Bureau
Chennai
,
Oct. 4
THE Chennai-based Orchid Chemicals & Pharmaceuticals Ltd has tied up with Mayne Pharma to market a selected range of Orchid's life-saving injectable antibiotic formulations in specific markets.
According to a press release from Orchid, the exclusive distribution alliance with Mayne Pharma, the injectable specialty pharmaceuticals division of the Mayne group Ltd listed on the Australian Stock Exchange, will cover the US, Canada, Europe and Australasia, which is a $1 billion market.
Orchid will exclusively develop and manufacture a range of injectable antibiotic formulations in specific dosage forms and strengths for distribution and marketing by Mayne.
Orchid is a market leader in cephalosporin and betalacturm antibiotic products, especially steriles, and is now set to diversify into niche products.
Mayne provides development funding to Orchid for the products and net profits from marketing will be shared, the release said.
Orchid recently entered the US market with the generic version of Ceftriaxone following its patent expiry. Orchid plans to expand its regulated market presence with launch of more sterile and oral products, the release said.
Article
E-Mail
::
Comment
::
Syndication
::
Printer Friendly Page
|
